| United Kingdom (govt)–Congenica: bioinformatics, 201905 supply existent processing of samples for 100,000 Genomes Project for Genomics England |
2019-05-14 |
| Philogen–Consilium: public relations, 201905 service existent by CSC |
2019-05-13 |
| Philogen–SEVERAL: investment, 201905 financing round €62m from existing + new private investors |
2019-05-13 |
| TreeFrog Therapeutics–Andrew Lloyd Associates: public relations, 201905 service existent by ALA |
2019-05-13 |
| TreeFrog Therapeutics–SEVERAL: investment, 201905 financing round Series A €6.5m led by XAnge + incl Galia Geston et al |
2019-05-13 |
| MabVax Therapeutics–BioNTech: investment, 201905 acquisition €na of antibody assets + infrastructure + lab equipment in San Diego |
2019-05-08 |
| Therachon–Cowen: investment, 201905 existing investor Cowen |
2019-05-08 |
| Therachon–France (govt): investment, 201905 existing investors Bpifrance + Inserm Transfert Initiative |
2019-05-08 |
| Therachon–Novo Group: investment, 201905 existing investor Novo Holdings |
2019-05-08 |
| Therachon–OrbiMed: investment, 201905 existing investor OrbiMed |
2019-05-08 |
| Therachon–Pfizer: investment, 201905 existing investor Pfizer Ventures |
2019-05-08 |
| Therachon–Pfizer: investment, 201905– acquisition 100% $340m upfront + $470m milestones excl apraglutide development program |
2019-05-08 |
| Therachon–Tekla Capital: investment, 201905 existing investor Tekla Capital Management LLC |
2019-05-08 |
| Therachon–Versant Ventures: investment, 201905 existing investor Versant Ventures |
2019-05-08 |
| Confo Therapeutics–BioGeneration Ventures: investment, 201905 financing round Series A totalling €30m incl new + lead investor BGV |
2019-05-07 |
| Confo Therapeutics–Capricorn Venture Partners: investment, 201905 financing round Series A totalling €30m incl existing + co-investor Capricorn HTF |
2019-05-07 |
| Confo Therapeutics–Flanders (govt): investment, 201905 financing round Series A totalling €30m incl existing + co-investor PMV |
2019-05-07 |
| Confo Therapeutics–Fund+: investment, 201905 financing round Series A totalling €30m incl new + co-investor Fund+ |
2019-05-07 |
| Confo Therapeutics–Perceptive Advisors: investment, 201905 financing round Series A totalling €30m incl new + co-investor Perceptive Advisors |
2019-05-07 |
| Confo Therapeutics–Qbic: investment, 201905 financing round Series A totalling €30m incl existing + co-investor Qbic |
2019-05-07 |
| Confo Therapeutics–SEVERAL: investment, 201905 financing round Series A €30m led by BGV + co-led by Wellington Partners |
2019-05-07 |
| Confo Therapeutics–Univ Michigan: investment, 201905 financing round Series A totalling €30m incl existing + co-investor MINTS |
2019-05-07 |
| Confo Therapeutics–V-Bio Ventures: investment, 201905 financing round Series A totalling €30m incl existing + co-investor V-Bio Ventures |
2019-05-07 |
| Confo Therapeutics–VIB: investment, 201905 financing round Series A totalling €30m incl existing + co-investor VIB |
2019-05-07 |
| Confo Therapeutics–Wellington Partners: investment, 201905 financing round Series A totalling €30m incl new + co-lead investor Wellington Partners |
2019-05-07 |
| Promethera–Ci:z Investment: investment, 201905 financing round Series D totalling €39.7m incl new + co-investor Ci:z Investment LLP (JP) |
2019-05-07 |
| Promethera–Korea Investment Partners: investment, 201905 financing round Series D totalling €39.7m incl new + co-investor Korea Investment Partners |
2019-05-07 |
| Promethera–Medipal: investment, 201905 financing round Series D totalling €39.7m incl new + co-investor Medipal Holdings Corp |
2019-05-07 |
| Promethera–Mirae Asset: investment, 201905 financing round Series D totalling €39.7m incl new + co-investor Mirae Asset Capital |
2019-05-07 |
| Promethera–Mitsui: investment, 201905 financing round Series D totalling €39.7m incl existing + co-investor Mitsui & Co Global Investment Inc |
2019-05-07 |
| Promethera–SEVERAL: investment, 201905 financing round Series D totalling €39.7m incl Belgian private investors as co-investors |
2019-05-07 |
| Promethera–SEVERAL: investment, 201905 financing round Series D €39.7m co-led by Itochu Corp + Shinsei Capital Partners |
2019-05-07 |
| Promethera–Shinsei Capital: investment, 201905 financing round Series D totalling €39.7m incl new + co-lead investor Shinsei Capital Partners |
2019-05-07 |
| Promethera–Six Snow: investment, 201905 financing round Series D totalling €39.7m incl new + co-investor family office Six Snow |
2019-05-07 |
| Abide Therapeutics–Lundbeck: investment, 201905– acquisition $250m upfront + $150m milestones of Abide by Lundbeck |
2019-05-06 |
| Cutech (IT)–Symrise: investment, 201905 acquisition of Cutech Srl by Symrise |
2019-05-06 |
| Devicare–SEVERAL: investment, 201905– crowdfunding comapaign via Capital Cell platform |
2019-05-06 |
| Chemical Solutions Ltd–SGS: investment, 201905 acquisition of CSL by SGS |
2019-05-03 |
| Diem Labs–Devicare: medical device, 201905– collab marketing of Lit-Control in the US by Diem Labs LLC |
2019-05-03 |
| Amal Therapeutics–Boehringer: cancer drugs, 201905– collab clinical research combi study of ATP128 + BI754091 in colorectal cancer |
2019-05-02 |
| AstraZeneca–Transgene: cancer immunotherapy, 201905– collab + license option $10m upfront developm armed oncolytic vaccinia viruses using Invir.IO |
2019-05-02 |
| miRdetect–Bremen (govt): investment, 201905 seed financing round 7-digit € from HTGF + BBM Bremen + a private investor |
2019-05-02 |
| miRdetect–High-Tech Gründerfonds: investment, 201905 seed financing round 7-digit € from HTGF + BBM Bremen + a private investor |
2019-05-02 |
| miRdetect–OTHER: investment, 201905 seed financing round 7-digit € from HTGF + BBM Bremen + a private investor |
2019-05-02 |
| miRdetect–SEVERAL: investment, 201905 seed financing round 7-digit € from HTGF + BBM Bremen + a private investor |
2019-05-02 |
| National Cancer Center (JP)–Fluidigm: mass cytometry, 201905 supply existent use of Hyperion Imaging System for I-O research |
2019-05-02 |
| Transgene–Huntsworth: public relations, 201905 service existent by Citigate Dewe Rogerson |
2019-05-02 |
| Alentis Therapeutics–Bellevue: investment, 201904 financing round Series A totalling CHF12.5m incl co-lead investor BB Pureos Bioventures |
2019-04-30 |
| Alentis Therapeutics–BioMedPartners: investment, 201904 financing round Series A totalling CHF12.5m incl co-lead investor BioMedPartners |
2019-04-30 |
| Alentis Therapeutics–France (govt): investment, 201904 financing round Series A totalling CHF12.5m incl co-investor Bpifrance |
2019-04-30 |
| Alentis Therapeutics–Instinctif Partners: public relations, 201904 service existent media relations by Instinctif |
2019-04-30 |
| Alentis Therapeutics–Schroders: investment, 201904 financing round Series A totalling CHF12.5m incl co-investor Schroder Adveq |
2019-04-30 |
| Alentis Therapeutics–SEVERAL: investment, 201904 financing round Series A CHF12.5m co-led by BioMedPartners + BB Pureos Bioventures |
2019-04-30 |
| Enzyre–EU (govt): grant, 201904 EFRO grant €2m |
2019-04-30 |
| Enzyre–Optimum Strategic Communications: public relations, 201904 service existent by Optimum |
2019-04-30 |
| Enzyre–SEVERAL: investment, 201904 closing of seed financing round |
2019-04-30 |
| SGS–Veeva Systems: clinical research software, 201904– supply global implementation of Veeva Vault CTMS by SGS |
2019-04-30 |
| Canopy Biosciences–Ampersand: investment, 201904 strategic growth investment from Ampersand Capital Partners |
2019-04-29 |
| JnJ–Iktos: drug discovery services, 201904– collab using AI technology for small molecule drug discovery projects Janssen |
2019-04-29 |
| Zellkraftwerk–Canopy Biosciences: investment, 201904 acquisition of Zellkraftwerk GmbH by Canopy Biosciences |
2019-04-29 |
| ADC Therapeutics–Adagene: antibody technology, 201904– collab + license agreem €na using SAFEbody technology for ADC development |
2019-04-24 |
| InfanDx–Arnika Beteiligungen: investment, 201904 financing round totalling up to €5.3m incl existing + co-investor Arnika Beteiligungen GmbH |
2019-04-24 |
| InfanDx–CVG Capital: investment, 201904 financing round totalling up to €5.3m incl new investor CVG Capital GmbH |
2019-04-24 |
| InfanDx–Life Science Inkubator: investment, 201904 financing round totalling up to €5.3m incl existing + co-investor LSI-Pre-Seed-Fonds GmbH |
2019-04-24 |
| InfanDx–SEVERAL: investment, 201904 financing round up to €5.3m milestone-based from Bamed MAM + CVG Capital + LSI PreSeed + Arnika Beteiligungen |
2019-04-24 |
| LabCorp–Biocartis: molecular diagnostics, 201904– collab ww €na offering of Idylla platform + oncology assays by Covance for drug development |
2019-04-23 |
| Poseida Therapeutics–Malin Corp: investment, 201904 financing round Series C totalling $142m incl existing + co-investor Malin Corp |
2019-04-22 |
| Poseida Therapeutics–Novartis: investment, 201904 financing round Series C totalling $142m incl $75m from lead investor Novartis Pharma AG |
2019-04-22 |
| Poseida Therapeutics–SEVERAL: investment, 201904 financing round Series C $142m led by Novartis with $75m |
2019-04-22 |
| Genecast (CN)–HalioDx: cancer test, 201904– distribution excl of Immunoscore Colon Assay in China by Genecast |
2019-04-19 |
| Arrakis Therapeutics–HBM: investment, 201904 financing round Series B totalling $75m incl new + co- investor HBM Healthcare Investments |
2019-04-18 |
| Arrakis Therapeutics–Nextech Invest: investment, 201904 financing round Series B totalling $75m incl co-lead investor Nextech Invest |
2019-04-18 |
| Arrakis Therapeutics–SEVERAL: investment, 201904 financing round Series B $75m co-led by VenBio Partners + Nextech Invest |
2019-04-18 |
| Aidoc–SEVERAL: investment, 201904 financing round Series B $27m led by Square Peg Capital |
2019-04-17 |
| Aidoc–Square Peg Capital: investment, 201904 financing round Series B totalling $27m incl lead investor Square Peg Capital |
2019-04-17 |
| Boehringer–PureTech Health: cancer immunotherapy, 201904– colllab research up to $226m + royalties using lymphatic targeting platform for I-O drugs |
2019-04-17 |
| CytoSen Therapeutics–Kiadis: investment, 201904– acquisition merger in shares with 1.94m shares (7.4%) upfront plus 5.82 shares milestones |
2019-04-17 |
| Hookipa–Bank of America: financial services, 201904 supply service BofA Merrill Lynch is joint book-running manager for IPO |
2019-04-17 |
| Hookipa–RBC Capital Markets: financial services, 201904 supply service RBC Capital Markets is joint book-running manager for IPO |
2019-04-17 |
| Hookipa–Silicon Valley Bank: financial services, 201904 supply service SVP Leerink is joint book-running manager for IPO |
2019-04-17 |
| Hookipa–Van Lanschot: financial services, 201904 supply service Kempen is co-manager for IPO |
2019-04-17 |
| Bruker Corp–Univ Nijmegen: mass spectrometry, 201904– collab establishment of joint Center of Excellence for Translational Omics at RUMC TML |
2019-04-16 |
| Cevec–SEVERAL: investment, 201904 financing round Series D from new + existing investors |
2019-04-16 |
| Univ Nijmegen–Bruker Corp: mass spectrometer, 201904 supply existent several Bruker MS systems at RUMC TML |
2019-04-16 |
| Univ Nijmegen–Bruker Corp: mass spectrometer, 201904c supply acquisition of timsTOF Pro IM-MS system by RUMC TML |
2019-04-16 |
| Catalent–Leonard Green & Partners: investment, 201904– up to $1b convertible preferred stock with $650m issued |
2019-04-15 |
| ETH Zürich–Agilent: mass spectrometer, 201904 supply new 6546 LC/Q-TOF MS system to lab of Nicola Zamboni |
2019-04-15 |
| Paragon Bioservices–Catalent: investment, 201904– acquisition 100% for $1.2b in cash on cash-free + debt-free basis |
2019-04-15 |
| Gilead–Novo Group: drug development, 201904– collab clinical research for NASH combining semaglutide + cilofexor + firsocostat Novo Nordisk |
2019-04-12 |
| Evotec–Indivumed: cancer drug discovery, 201904– collab strategic precision medicine for new colorectal cancer drugs |
2019-04-11 |
| Miracogen (CN)–Synaffix: ADC technology, 201904– license up to $125m + royalties for GlycoConnect + HydraSpace ADC technologies to Shanghai Miracogen |
2019-04-10 |
| DKSH–Bruker Corp: analytical instruments, 201904– distribution excl extension for Bruker AXS products by DKSH in China |
2019-04-09 |
| Probiodrug–SEVERAL: investment, 201904 private placement €8.2m with 4.1m new shares at €2m led by Claus Christiansen et al. |
2019-04-09 |
| Theranexus–IRISA (FR): bioinformatics, 210904– collab using AI for targeting neuroglial interactions for drug discovery with Dyliss Group |
2019-04-09 |
| Phenex–Helmholtz: drug research, 201904– collab joint research in NASH + liver cancer metabolism with Heikenwälder Group at DKFZ |
2019-04-05 |
| Gesynta Pharma–SEVERAL: investment, 201904 financing round €6m led by Industrifonden + incl group of private life science investors |
2019-04-04 |
| Gesynta Pharma–Sweden (govt): investment, 201904 financing round totalling €6m incl lead investor Industrifonden |
2019-04-04 |
| AgomAb Therapeutics–Advent France Biotechnology: investment, 201904 financing round Series A totalling €21m incl co-lead investor Advent France |
2019-04-03 |
| AgomAb Therapeutics–Argenx: therapeutic antibodies, 201904– license excl to HGF-mimetic SIMPLE Antibodies developed in partnership |
2019-04-03 |
| AgomAb Therapeutics–Boehringer: investment, 201904 financing round Series A totalling €21m incl co-investor BIVF |
2019-04-03 |
![[LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal](/images/basics/lse-life-sciences-europe-portal-logo-2011.jpg){kind=logo}
Date![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px](/banner/iito-20181119-600-060-lsus-life-sciences-usa-com-beta.jpg)
![Picture [LSUK] Life-Sciences-UK.com – The Business Web Portal 600x80px](/banner/iito-20150802-600-080-lsuk-life-sciences-uk-com.jpg)
![Picture [iito] LSUS iitoLifeScience Transatlantic Life Sciences 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 120x600px](/banner/iito-20181119-120-600-msc-mass-spec-capital-com.jpg)
